Serum amyloid A1 (SAA1) and serum amyloid A2 (SAA2), which were significantly upregulated in both the acute and subacute phases, have been reported to be severity-related biomarkers in ARDS due to COVID-19 [19, 20]. This evidence concerns the gene SAA1 and COVID-19.